Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Sales | 11,785,000 | 12,606,000 | 12,341,000 | 12,679,000 | 11,810,000 |
| Cost of Goods | 4,105,000 | 4,489,000 | 4,368,000 | 4,451,000 | 4,212,000 |
| Gross Profit | 7,680,000 | 8,117,000 | 7,973,000 | 8,228,000 | 7,598,000 |
| Operating Expenses | 5,758,000 | 6,662,000 | 5,704,000 | 6,135,000 | 5,147,000 |
| Operating Income | 1,922,000 | 1,455,000 | 2,269,000 | 2,093,000 | 2,451,000 |
| Interest Expense | 180,000 | 168,000 | 174,000 | 180,000 | 185,000 |
| Other Income | 205,000 | -209,000 | 179,000 | 200,000 | 86,000 |
| Pre-tax Income | 1,947,000 | 1,078,000 | 2,274,000 | 2,113,000 | 2,352,000 |
| Income Tax | 282,000 | 142,000 | 329,000 | 307,000 | 341,000 |
| Net Income Continuous | 1,665,000 | 936,000 | 1,945,000 | 1,806,000 | 2,011,000 |
| Minority Interests | -1,000 | 7,000 | 5,000 | 2,000 | 0 |
| Net Income | $1,666,000 | $929,000 | $1,940,000 | $1,804,000 | $2,011,000 |
| EPS Basic Total Ops | 0.70 | -0.80 | 0.81 | 0.76 | 0.85 |
| EPS Basic Continuous Ops | 0.70 | -0.79 | 0.82 | 0.76 | 0.85 |
| EPS Diluted Total Ops | 0.70 | -0.80 | 0.81 | 0.75 | 0.84 |
| EPS Diluted Continuous Ops | 0.70 | -0.78 | 0.81 | 0.75 | 0.84 |
| EBITDA(a) | $1,922,000 | $3,155,000 | $3,777,000 | $3,559,000 | $3,820,000 |